Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MWSEV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
NN-3201
|
|||||
| Synonyms |
NN 3201; NN3201
Click to Show/Hide
|
|||||
| Organization |
Novelty Nobility, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 4 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Clinical candidate
Chronic myelogenous leukemia [ICD11:2A20]
Clinical candidate
Gastrointestinal stromal tumor [ICD11:2B5B]
Clinical candidate
Small cell lung cancer [ICD11:2C25]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Mast/stem cell growth factor receptor Kit (KIT)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
This linker system utilizes a cysteine re-bridging technology to produce site-specific conjugation with high DAR homogeneity.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.